Search Results

The specialty pharmaceutical company has twice filed for bankruptcy in recent years, driven by opioid-related litigation. Mallinckrodt’s deal with CVC will allow it to pay off more than half of its net debt.

Mallinckrodt plc, a global specialty pharmaceutical company, reported its financial results for the first quarter ended March 29, 2024.

Mallinckrodt plc (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ended December 29, 2023.

Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of three posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 European Association for the Study of the Liver Congress taking place in Milan, Italy from June 5-8, 2024.

Mallinckrodt plc, a global specialty pharmaceutical company, announced the presentation of two posters on TERLIVAZ® for injection in patients with hepatorenal syndrome with rapid reduction in kidney function1 at the 2024 Digestive Disease Week® taking place in Washington, DC from May 18-21, 2024.

Mallinckrodt plc, a global specialty pharmaceutical company, announced that Paul O’Neill has been appointed Executive Vice President, Quality & Operations, Specialty Brands, effective immediately.

Mallinckrodt plc today announced the appointments of Paul Bisaro, Katina Dorton, Abbas Hussain and Wesley Wheeler to its Board of Directors, effective immediately.

Mallinckrodt plc, a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Mallinckrodt’s supplemental New Drug Application (sNDA) for the Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector.